Probiotic as a Novel Treatment Strategy Against Liver Disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
CONTEXT: A symbiotic relationship between the liver and intestinal tract enables the healthy status of both organs. Microflora resident in intestinal lumen plays a significant role in hepatocytes function. Alterations to the type and amount of microorganisms that live in the intestinal tract can result in serious and harmful liver dysfunctions such as cirrhosis, nonalcoholic fatty liver disease, alcoholic liver disease, and hepatic encephalopathy. An increased number of pathogens, especially enterobacteriaceae, enterococci, and streptococci species causes the elevation of intestinal permeability and bacterial translocation. The presence of high levels of lipopolysaccharide (LPS) and bacterial substances in the blood result in a portal hypertension and ensuing hepatocytes damage. Several methods including the usage of antibiotics, prebiotics, and probiotics can be used to prevent the overgrowth of pathogens. Compared to prebiotic and antibiotic therapy, probiotics strains are a safer and less expensive therapy. Probiotics are "live microorganisms (according to the FAO/WHO) which when administered in adequate amounts confer a health benefit on the host". EVIDENCE ACQUISITIONS: Data from numerous preclinical and clinical trials allows for control of the flora bacteria quantity, decreases in compounds derived from bacteria, and lowers proinflammatory production such as TNF-α, IL-6 and IFN-γ via down-regulation of the nuclear factor kappa B (NF-κ B). RESULTS: On the other hand, probiotic can reduce the urease activity of bacterial microflora. Furthermore, probiotic decreases fecal pH value and reduces ammonia adsorption. In addition, the serum level of liver enzymes and other substances synthesized by the liver are modulated subsequent to probiotic consumption. CONCLUSIONS: According to our knowledge, Probiotic therapy as a safe, inexpensive and a noninvasive strategy can reduce pathophysiological symptoms and improve different types of liver diseases without side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of the Human Infant Intestinal Microbiota
Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A., & Brown, P. O. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050177 · Cited by 2,877
Probiotics and their fermented food products are beneficial for health
Parvez, S., Malik, K. A., Ah Kang, S., & Kim, H.-Y. (2006) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2006.02963.x · Cited by 1,435
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434 · cited 1×
“However, it is not an appropriate therapy because of the unspecific ramifications to any bacteria (72).”
BackgroundIncreased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia
Guarner, C., Soriano, G., Tomas, A., Bulbena, O., Novella, M. T., Balanzo, J., Vilardell, F., Mourelle, M., & Moncada, S. (1993) · Hepatology · doi:10.1002/hep.1840180520 · Cited by 489
Fukui, H., Brauner, B., Bode, J. C., & Bode, C. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90933-3 · Cited by 461 · cited 1×
“Furthermore, a high level of endotoxin has been seen in the plasma of these patients (41-45).”
BackgroundLumsden, A. B., Henderson, M. J., & Kutner, M. H. (1988) · Hepatology · doi:10.1002/hep.1840080207 · Cited by 427 · cited 1×
“Furthermore, a high level of endotoxin has been seen in the plasma of these patients (41-45).”
BackgroundEffect of alcohol consumption on the gut.
Bode, C., & Christian Bode, J. (2003) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/s1521-6918(03)00034-9 · Cited by 379
Lee, H.-Y., Park, J.-H., Seok, S.-H., Baek, M.-W., Kim, D.-J., Lee, K.-E., Paek, K.-S., Lee, Y., & Park, J.-H. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.05.007 · Cited by 342 · cited 1×
“Animal models mice fed HFD / 8 w Lactobacillus rhamnosus PL60 liver steatosis, improved histological steatosis manifestation (83)”
MethodGupta, V, & Garg, R. (2009) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.53201 · Cited by 283
Prebiotics and probiotics; modifying and mining the microbiota
Quigley, E. M. M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.004 · Cited by 238 · cited 1×
“Increase in the pathogen population due to malfunction of microflora may lead to severe systematic infections (9).”
BackgroundWang, Y., Xu, N., Xi, A., Ahmed, Z., Zhang, B., & Bai, X. (2009) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2012-x · Cited by 200
El-Nezami, H. S., Polychronaki, N. N., Ma, J., Zhu, H., Ling, W., Salminen, E. K., Juvonen, R. O., Salminen, S. J., Poussa, T., & Mykkänen, H. M. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.5.1199 · Cited by 184
Gut microbiota and probiotics in chronic liver diseases
Cesaro, C., Tiso, A., Del Prete, A., Cariello, R., Tuccillo, C., Cotticelli, G., del Vecchio Blanco, C., & Loguercio, C. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.015 · Cited by 182
Madrid, A. M., Hurtado, C., Venegas, M., Cumsille, F., & Defilippi, C. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03636.x · Cited by 158
Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study
Vleggaar, F. P., Monkelbaan, J. F., & van Erpecum, K. J. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282f5197e · Cited by 110 · cited 1×
“In addition, bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase, aspartate aminotransferase, alanine aminotransferase, prothrombin, albumin, and bile salts levels were not significantly different between the probiotic and placebo groups (79).”
Background
Cited by
The effects of probiotics in lactose intolerance: A systematic review
Oak, S. J., & Jha, R. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1425977 · Cited by 318
Changes in Glutathione Content in Liver Diseases: An Update
Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021) · Antioxidants · doi:10.3390/antiox10030364 · Cited by 313
Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers
Madsen, B. S., Havelund, T., & Krag, A. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0044-1 · Cited by 38
“An accumulating body of evidence also suggests that treatment with probiotics has beneficial effects on a variety of liver diseases and could be a safe strategy to address the intestinal dysbiosis seen in this setting [98].”
BackgroundEvaluation of the Role of Probiotics As a New Strategy to Eliminate Microbial Toxins: A Review
Ghadaksaz, A., Nodoushan, S. M., Sedighian, H., Behzadi, E., & Fooladi, A. A. I. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09893-2 · Cited by 20
Self-citation
Metadata
- Authors
- Imani Fooladi, A. A., Hosseini, H. M., Nourani, M. R., Khani, S., & Alavian, S. M.
- Venue
- Hepatitis Monthly
- Publisher
- Brieflands
- Published
- 2013-02-25
- Volume
- 13
- Issue
- 2
- Pages
- e7521-e7521
- ISSN
- 1735-143X (ISSN-L)
- 1735-3408
- OpenAlex
- W1965878971
- Cited by
- 87
- References
- 15
- FWCI
- 14.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.